Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alamar BiosciencesALMR +8.84%12 5-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates ALMR with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 637 Medical Devices & Instruments companies, Alamar Biosciences ranks worse than 156985.71% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Alamar Biosciences's current 5-Year Share Buyback Ratio was 0.00%.
ALMR's 5-Year Share Buyback Ratio is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: -3.3 * Ranked among companies with meaningful 5-Year Share Buyback Ratio only.
Alamar Biosciences (NAS:ALMR) 5-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Alamar Biosciences 5-Year Share Buyback Ratio Related Terms
ALMR vs ESTA, NVCR, BFLY: 5-Year Share Buyback Ratio Comparison
For the Medical Devices subindustry, Alamar Biosciences's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alamar Biosciences 5-Year Share Buyback Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alamar Biosciences's 5-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Alamar Biosciences's 5-Year Share Buyback Ratio falls into.
Alamar Biosciences 5-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 5-Year Share Buyback Ratio of 0.00 mean?
Alamar Biosciences (ALMR) has a 5-Year Share Buyback Ratio of 0.00 as of Jun. 2026. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Alamar Biosciences and its competitors. According to the industry distribution chart, Alamar Biosciences ranks #999999 out of 637 companies in the Medical Devices & Instruments industry.
Is Alamar Biosciences' 5-Year Share Buyback Ratio too high?
Alamar Biosciences' current 5-Year Share Buyback Ratio is 0.00. Based on the distribution chart, Alamar Biosciences ranks #999999 out of 637 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Alamar Biosciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alamar Biosciences' 5-Year Share Buyback Ratio compare to ESTA and NVCR?
According to the Medical Devices & Instruments industry distribution chart, Alamar Biosciences ranks #999999 out of 637 companies for 5-Year Share Buyback Ratio. This places Alamar Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 5-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 5-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Share Buyback Ratio mean?
A high 5-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. View historical data for Alamar Biosciences and its competitors. Alamar Biosciences's current 5-Year Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alamar Biosciences stock overvalued right now?
Alamar Biosciences (ALMR) has a current 5-Year Share Buyback Ratio of 0.00. The current 5-Year Share Buyback Ratio is 0.00. Alamar Biosciences' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Share Buyback Ratio calculated?
5-Year Share Buyback Ratio is calculated from a company's financial statements. For Alamar Biosciences (ALMR), the current 5-Year Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
12GF Score
Get the complete analysis for ALMR
5-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALMR has been successfully added to your 
